Back to top
more

Aspira Women's Health (AWH)

(Delayed Data from NSDQ)

$3.28 USD

3.28
6,352

-0.12 (-3.53%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $3.29 +0.01 (0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo (MASI) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 31.58% and 0.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aspira (AWH) and Compugen (CGEN) have performed compared to their sector so far this year.

All You Need to Know About Aspira (AWH) Rating Upgrade to Buy

by Zacks Equity Research

Aspira (AWH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ReWalk Robotics (RWLK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ReWalk (RWLK) delivered earnings and revenue surprises of 28.57% and 0.15%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 3.85% and 44.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) Lags Q4 Earnings Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of -33.33% and 0.37%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?

Aspira (AWH) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Aspira (AWH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aspira (AWH) delivered earnings and revenue surprises of -1,360% and 0.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for May 11th

by Zacks Equity Research

AMEH, PYCR, AWH, SAND and MCD have been added to the Zacks Rank #1 (Strong Buy) List on May 11, 2023.

Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

by Zacks Equity Research

Here is how Cardinal Health (CAH) and Aspira (AWH) have performed compared to their sector so far this year.

What Makes Aspira (AWH) a New Buy Stock

by Zacks Equity Research

Aspira (AWH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aspira (AWH) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aspira (AWH) delivered earnings and revenue surprises of 33.33% and 10.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Has Aspira Women's Health (AWH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aspira (AWH) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 16.67% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?

by Zacks Equity Research

Here is how Editas Medicine (EDIT) and Aspira (AWH) have performed compared to their sector so far this year.

Alphatec (ATEC) Soars 8.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

KORU Medical Systems Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 40% and 11.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 20.83% and 6.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Aspira (AWH) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Aspira (AWH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Down 38.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Aspira (AWH)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Aspira (AWH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Intuitive (ISRG) New Lung Biopsy Imaging Technology Gets FDA Nod

by Zacks Equity Research

The FDA clears the integration of mobile cone-beam CT imaging technology with Intuitive's (ISRG) Ion Endoluminal System, enhancing a physician's ability to provide minimally invasive lung biopsy.

Aspira (AWH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aspira (AWH) delivered earnings and revenue surprises of 0% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?